RÉSUMÉ
A number of recent studies have emphasized the potential value of flow cytometry [FCM] as a "marker" to assess the malignity behavior of neoplasm, including bone tumors. In this study, flow cytometry analysis of 50 cases of osteosarcoma was done by means of preparation of nuclear suspension technique. A total of 125 specimens were analyzed. The 25 non-neoplastic tissue specimens taken away from the tumor and used as control had diploid amount of DNA, whereas all the tumor biopsies were DNA aneuploid with DNA indices ranging from 1.17 to 3.5 with a median of 1.74. Our findings demonstrate that flow cytometric DNA analysis is practical in osteosarcoma and support the observations of others that abnormal DNA content may serve as a general neoplastic marker in these tumors